Lymphoma Clinical Trials in Houston

Showing 241-260 of 533 trials

Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma

NCT02031419

First study, at multiple clinical centers, exploring the effects of different combinations of compounds (CC-122, CC-223 ,CC-292 and rituximab) to treat Diffuse Large B Cell Lymphoma (DLBCL) and Follicular Lymphoma

Lymphoma, Large B-Cell, Diffuse

Celgene174 participantsStarted Dec 2013

Stanford, California, United States • New Haven, Connecticut, United States • Tampa, Florida, United States +13 more locations

TERMINATEDPhase 1/2< 1 mile

Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies

NCT03422679

This is a phase I/II, non randomized, open-label, dose escalation study to investigate the safety, tolerability and preliminary efficacy of CB-103.

Breast CancerColorectal CancerAdenoid Cystic Carcinoma+5 more

Cellestia Biotech AG79 participantsStarted Dec 2017

Santa Monica, California, United States • Boston, Massachusetts, United States • Houston, Texas, United States +14 more locations

Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma

Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies

Lymphoma Trials in Other Cities

Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A

Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)

Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell Therapy

BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma

Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

A Phase 1a Study Evaluating the Safety, Tolerability, and Efficacy of IBI322 in Subjects With Advanced Cancers

Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma

Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma

A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma

A Study of BTX-1188 in Subjects With Advanced Malignancies

Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma

A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors

Patient-Derived Xenografts in Personalizing Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma

Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression Risk

A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma

Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma

Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma

Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma

Other Conditions in Houston